ImmunityBio (IBRX) announced the opening of a new Phase 2 study to assess the BioShield platform, anchored by Anktiva, in patients with long COVID.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
- ImmunityBio announces early findings from QUILT-106 trial
- ImmunityBio says VA hospital among first to administer ANKTIVA
- ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
- ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating